Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance
Open accessThe DOI matches its Crossref record; 42 of the 45 references it cites were found in a registry or an index.
Abstract
The development of HIV integrase (IN) strand transfer inhibitors (INSTIs) and our understanding of viral resistance to these molecules have been hampered by a paucity of available structural data. We recently reported cocrystal structures of the prototype foamy virus (PFV) intasome with raltegravir and elvitegravir, establishing the general INSTI binding mode. We now present an expanded set of cocrystal structures containing PFV intasomes complexed with first- and second-generation INSTIs at resolutions of up to 2.5 Å. Importantly, the improved resolution allowed us to refine the complete coordination spheres of the catalytic metal cations within the INSTI-bound intasome active site. We show that like the Q148H/G140S and N155H HIV-1 IN variants, the analogous S217H and N224H PFV INs display reduced sensitivity to raltegravir in vitro. Crystal structures of the mutant PFV intasomes in INSTI-free and -bound forms revealed that the amino acid substitutions necessitate considerable conformational rearrangements within the IN active site to accommodate an INSTI, thus explaining their adverse effects on raltegravir antiviral activity. Furthermore, our structures predict physical proximity and an interaction between HIV-1 IN mutant residues His148 and Ser/Ala140, rationalizing the coevolution of Q148H and G140S/A mutations in drug-resistant viral strains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The oxadiazole group of raltegravir, unique to this inhibitor, stacks with the side chain of Tyr143, explaining why amino acid substitutions such as Y143R/C cause resistance to this drug161.”
From Structure and function of retroviral integrase (2022) · cites this paper as [161]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The mode of action of these compounds was visualized in crystals of the PFV intasome25,161,162 and later refined in HIV-1 and SIV cryo-EM structures35,36.”
From Structure and function of retroviral integrase (2022) · cites this paper as [161]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The PFV intasome crystal structures reported in the early 2010s supercharged the field of retroviral integration structural biology25,29,161.”
From Structure and function of retroviral integrase (2022) · cites this paper as [161]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742 · cited 3×
“The final WT:Mn structure was used as a starting point for building the Mn2+-bound mutant and WT:MK2048 structures, which were all refined using a combination of manual editing in Coot and restrained refinement in Refmac.”
MethodInfluentialMolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson, J. S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm216 · Cited by 3,896
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 1×
“All INSTIs described to date are structurally related to the predecessor diketo acid and naphthyridine carboxamide scaffolds (12, 13).”
BackgroundRetroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678 · cited 10×
“Consistent with our previous results (6), the INSTIs bind to the active site, displacing the 3′-hydroxyl group (and indeed the entire 3′terminal nucleotide of viral DNA) and thereby inactivating the intasome (Fig.”
BackgroundMethodResultInfluentialSelf-citationSumma, V., Petrocchi, A., Bonelli, F., Crescenzi, B., Donghi, M., Ferrara, M., Fiore, F., Gardelli, C., Gonzalez Paz, O., Hazuda, D. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800245z · Cited by 633 · cited 3×
“1): raltegravir (14), L-870,810 (13), PICA (27), GS9160 (28), MK0536 (29), MK2048 (30), 1 (30), and 2 (31).”
BackgroundMiller, M. D., Farnet, C. M., & Bushman, F. D. (1997) · Journal of Virology · doi:10.1128/jvi.71.7.5382-5390.1997 · Cited by 620 · cited 1×
“The reactions catalyzed by IN proceed in the context of the preintegration complex (PIC), a poorly characterized nucleoprotein assembly, which in addition to IN and viral DNA contains other viral as well as cellular components (3, 4).”
BackgroundNowotny, M., Gaidamakov, S. A., Crouch, R. J., & Yang, W. (2005) · Cell · doi:10.1016/j.cell.2005.04.024 · Cited by 620 · cited 1×
“During the strand transfer reaction, metal B would be in position to activate the 3′ hydroxyl of the viral DNA for nucleophilic attack on a target DNA phosphodiester, with metal A stabilizing the hypothetical pentacovalent phosphorus transition state (25, 26).”
BackgroundKulkosky, J., Jones, K. S., Katz, R. A., Mack, J. P., & Skalka, A. M. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.5.2331 · Cited by 571 · cited 2×
“However, due to the high level of conservation between retroviral INs, in particular within their active sites (6, 8, 9, 17), PFV IN can serve as a convenient proxy for structural studies of HIV INSTIs (18, 19).”
Background
Research works printed but not linked: 7
- R Craigie, Retroviral DNA integration. Mobile DNA II, eds NL Craig, R Craigie, M Gellert, AM Lambowitz (ASM Press, Washington, DC), pp. 613–630 (2002).
- J Vacca, et al., Discovery of MK-2048—subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitors. Fourth International AIDS Socienty Conference (Sydney, 2007).
- D Hazuda, M Miller, B Nguyen, J Zhao, Resistance to the HIV-integrase inhibitor raltegravir: Analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1 infection. XVI International HIV Drug Resistance Workshop (St Michael, Barbados, 2007).
- VA Johnson, et al., Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 17, 138–145 (2009).
- JA Grobler, K Stillmock, MD Miller, DJ Hazuda, Mechanism by which the HIV integrase active-site mutation N155H confers resistance to raltegravir. Antivir Ther 13, A41 (2008).
- JW Evans, et al. Processes and intermediates useful for preparing integrase inhibitor compounds, US Patent Appl US2008/0039487. (2008).
- JS Wai, et al., Next generation of inhibitors of HIV-1 integrase strand transfer inhibitor: Structural diversity and resistance profiles. 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles, 2007).
Cited by
HIV-1 Antiretroviral Drug Therapy
Arts, E. J., & Hazuda, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007161 · Cited by 851
“Loss of Raltegravir susceptibility of HIV-1 is conferred by multiple non-overlapping genetic pathways.”
BackgroundInfluentialThe structural biology of HIV-1: mechanistic and therapeutic insights
Engelman, A., & Cherepanov, P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2747 · Cited by 424
“The clinically approved HIV-1 IN inhibitor, raltegravir, and similar small molecules that are in development preferentially inhibit DNA strand transfer activity; fortuitously, IN strand transfer inhibitors (INSTIs) harbour broad antiretroviral activit”
BackgroundSelf-citationHare, S., Smith, S. J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S. H., & Cherepanov, P. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.073189 · Cited by 264
“Our previous S217H and N224H intasome structures obtained in the presence and absence of MK-2048 showed that these amino acid substitutions cause subtle shifts in active site geometry and that binding of the INSTI causes remodeling of the mutant active sites (Hare et al., 2010b).”
BackgroundMethodInfluentialSelf-citationInterfacial inhibitors: targeting macromolecular complexes
Pommier, Y., & Marchand, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3404 · Cited by 259
“Stunning co-crystal structures of integrase with its viral substrates have revealed the trapping of the integrase–DNA complex as the drugs bind at its interfac”
Lesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Self-citation
Metadata
- Authors
- Hare, S., Vos, A. M., Clayton, R. F., Thuring, J. W., Cummings, M. D., & Cherepanov, P.
- Affiliations
- Imperial College London (GB)
- Tibotec BVBA, 2340 Beerse, Belgium
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2010-10-28
- Volume
- 107
- Issue
- 46
- Pages
- 20057-20062
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2993412
- OpenAlex
- W2117072114
- Cited by
- 305
- References
- 45
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 11 · 2023: 10 · 2022: 10 · 2021: 27 · 2020: 20 · 2019: 16 · 2018: 13 · 2017: 15 · 2016: 13 · 2015: 26 · 2014: 31 · 2013: 31 · 2012: 38
- FWCI
- 21.36
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- Figshare (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- HIV integrase, integrase strand transfer inhibitors, drug resistance, raltegravir, elvitegravir, co-crystal structure, conformational change, antiviral activity
- MeSH terms
- Raltegravir Potassium, Mutation, Pyrrolidinones, Retroviridae, HIV-1, Evolution, Molecular, Integrases, HIV Integrase Inhibitors, Amino Acid Substitution, Inhibitory Concentration 50, Catalytic Domain, Drug Resistance, Viral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. https://app.cochat.ai/papers/10.1073/pnas.1010246107
- The paper
- Hare, S., Vos, A. M., Clayton, R. F., Thuring, J. W., Cummings, M. D., & Cherepanov, P. (2010). Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1010246107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.